Edition:
United Kingdom

Conatus Pharmaceuticals Inc (CNAT.OQ)

CNAT.OQ on NASDAQ Stock Exchange Global Market

5.15USD
23 Feb 2018
Change (% chg)

$-0.02 (-0.39%)
Prev Close
$5.17
Open
$5.16
Day's High
$5.22
Day's Low
$5.02
Volume
59,895
Avg. Vol
80,262
52-wk High
$9.40
52-wk Low
$3.88

Latest Key Developments (Source: Significant Developments)

Conatus Pharmaceuticals reports Q3 revenue of $9.6 million
Wednesday, 1 Nov 2017 

Nov 1 (Reuters) - Conatus Pharmaceuticals Inc :Conatus Pharmaceuticals Inc reports third quarter 2017 financial results and program updates.Q3 revenue $9.6 million.Q3 revenue view $16.1 million -- Thomson Reuters I/B/E/S.Conatus Pharmaceuticals Inc - qtrly ‍net loss per share $0.13.  Full Article

EMA grants Conatus orphan drug designation for IDN-7314 for the treatment of PSC
Wednesday, 18 Oct 2017 

Oct 19 (Reuters) - Conatus Pharmaceuticals Inc :EMA grants Conatus orphan drug designation for IDN-7314 for the treatment of PSC.Conatus Pharmaceuticals - ‍continue to evaluate potential internal, external opportunities with goal of announcing initial pipeline expansion plans later in 2017​.  Full Article

Conatus Pharmaceuticals Inc qtrly loss per share $0.30
Wednesday, 3 Aug 2016 

Conatus Pharmaceuticals Inc : Conatus pharmaceuticals reports second quarter 2016 financial results and program updates . Conatus pharmaceuticals inc qtrly loss per share $0.30 .Q2 earnings per share view $-0.38 -- Thomson Reuters I/B/E/S.  Full Article

BRIEF-Conatus Pharmaceuticals reports Q3 revenue of $9.6 million

* Conatus Pharmaceuticals Inc reports third quarter 2017 financial results and program updates